Osteoporosis, inflammation and ageing

Immunity & Ageing

Massimo De Martinis¹  Maria Cristina Di Benedetto¹  Lia Ginaldi¹ 

[1] Department of Internal Medicine, University of L'Aquila, Italy

关键词: Osteoporosis;    Bone remodelling;    Cytokines;    Inflammation;    Ageing;   

Others  :  819692
DOI  :  10.1186/1742-4933-2-14

 received in 2005-08-31, accepted in 2005-11-04,  发布年份 2005

【 摘 要 】

Osteoporosis is a condition characterized by low bone mass and increased bone fragility, putting patients at risk of fractures, which are major causes of morbidity substantially in older people. Osteoporosis is currently attributed to various endocrine, metabolic and mechanical factors. However, emerging clinical and molecular evidence suggests that inflammation also exerts significant influence on bone turnover, inducing osteoporosis. Numerous proinflammatory cytokines have been implicated in the regulation of osteoblasts and osteoclasts, and a shift towards an activated immune profile has been hypothesized as important risk factor. Chronic inflammation and the immune system remodelling characteristic of ageing, as well as of other pathological conditions commonly associated with osteoporosis, may be determinant pathogenetic factors. The present article will review the current perspectives on the interaction between bone and immune system in the elderly, providing an interpretation of osteoporosis in the light of inflamm-ageing.

【 授权许可】

   
2005 Ginaldi et al; licensee BioMed Central Ltd.

【 参考文献 】

• [1]Delmas PD: Treatment of postmenopausal osteoporosis. Lancet 2002, 359:2018-26.
• [2]Yun AJ, Lee PY: Maladaptation of the link between inflammation and bone turnover may be a key determinant of osteoporosis. Med Hypotheses 2004, 63:532-537.
• [3]Arron JR, Choi Y: Bone versus immune system. Nature 2000, 408:535-6.
• [4]Lorenzo J: Interactions between immune and bone cells: new insights with many remaining questions. J Clin Invest 2000, 106:749-52.
• [5]Mitra D, Elvins DM, Speden DJ, Collins AJ: The prevalence of vertebral fractures in mild ankylosing spondylitis and their relationship to bone mineral density. Rheumatology 2000, 39:85-9.
• [6]Haugeberg G, Lodder MC, Lems WF, Uhlig T, Orstavik RE, Dijkmans BA, Kvien TK, Woolf AD: Hand cortical bone mass and its associations with radiographic joint damage and fractures in 50–70 year old female patients with rheumatoid arthritis: cross sectional Oslo-Truro-Amsterdam (OSTRA) collaborative study. Ann Rheum Dis 2004, 63:1331-4.
• [7]Bultink IE, Lems WF, Kostense PJ, Dijkmans BA, Voskuyl AE: Prevalence of and risk factors for low bone mineral density and vertebral fractures in patients with systemic lupus erythematosus. Arthritis Rheum 2005, 52:2044-50.
• [8]Mikuls TR, Saag KG, Curtis J, Bridges SL Jr, Alarcon GS, Westfall AO, Lim SS, Smith EA, Jonas BL, Moreland LW, CLEAR investigators: Prevalence of osteoporosis and osteopenia among African Americans with early rheumatoid arthritis: the impact of ethnic-specific normative data. J Natl Med Assoc 2005, 97:1155-60.
• [9]Walsh NC, Gravallese EM: Bone loss in inflammatory arthritis: mechanisms and treatment strategies. Curr Opin Rheumatol 2004, 16:419-27.
• [10]Annapoorna N, Rao GV, Reddy NS, Rambabu P, Rao KR: An increased risk of osteoporosis during acquired immunodeficiency syndrome. Int J Med Sci 2004, 1:152-164.
• [11]Leung DY, Geha RS: Clinical and immunologic aspects of the hyperimmunoglobulin E syndrome. Hematol Oncol Clin North Am 1988, 2:81-100.
• [12]Jensen T, Klarlund M, Hansen M, Jensen KE, Skjodt H, Hydlldstrup L: Connective tissue metabolism in patients with unclassified polyarthritis and early rheumatoid arthritis. Relationship to disease activity, bone mineral density, and radiographyc outcome. J Rheumatol 2004, 31:1698-1708.
• [13]Abrahamsen B, Andersen I, Christensen SS, Skov Madsen J, Brixen K: Utility of testing for monoclonal bands in serum of patients with suspected osteoporosis: retrospective, cross sectional study. BMJ 2005, 330:818.
• [14]Moschen AR, Kaser A, Enrich B, Ludwiczek O, Gabriel M, Obrist P, Wolf AM, Tilg H: The RANKL/OPG system is activated in inflammatory bowel disease and relates to the state of bone loss. Gut 2005, 54:479-87.
• [15]Ishihara K, Hirano T: IL-6 in autoimmune disease and chronic inflammatory proliferative disease. Cytokine Growth Factor Rev 2002, 13:357-68.
• [16]Moschen AR, Kaser A, Enrich B, Ludwiczek O, Gabriel M, Obrist P, Wolf AM, Tilg H: RANKL/OPG system is activated in inflammatory bowel disease and relates to the state of bone loss. Gut 2005, 54:479-87.
• [17]Koh JM, Kang YH, Jung CH, Bae S, Kim DJ, Chung YE, Kim GS: Higher circulating hsCRP levels are associated with lower bone mineral density in healthy pre-and postmenopausal women: evidence for a link between systemic inflammation and osteoporosis. Osteoporosis Int 2005., doi10.1007/s00198-005-1840-5
• [18]Muller B: Cytokine imbalance in non immunological chronic disease. Cytokine 2002, 18:334-339.
• [19]Ganesan K, Teklehaimanot S, Tran TH, Asuncion M, Norris K: Relationship of C-reactive protein and bone mineral density in community-dwelling elderly females. J Natl Med Assoc 2005, 97:329-33.
• [20]Saidenberg-Kermanac'h N, Cohen-Solal M, Bessis N, De Vernejoul MC, Boissier MC: Role for osteoprotegerin in rheumatoid inflammation. Joint Bone Spine 2004, 71:9-31.
• [21]Franceschi C, Bonafè M, Valensin S, Olivieri F, De Luca M, Ottaviani E, De Benedictis G: Inflamm-ageing. An evolutionary perspective on immunosenescence. Ann N Y Acad Sci 2000, 908:244-54.
• [22]Kiecolt-Glaser JK, Preacher KJ, MacCallum RC, Atkinson C, Malarkey WB, Glaser R: Chronic stress and age-related increases in the proinflammatory cytokine IL-6. Proc Natl Acad Sci USA 2003, 100:9090-5.
• [23]Goldring SR: Inflammatory mediators as essential elements in bone remodeling. Calcif Tissue Int 2003, 73:97-100.
• [24]Siggelkow H, Eidner T, Lehmann G, Viereck V, Raddarz D, Munzel U, Hein G, Hufner M: Cytokines, osteoprotegerin, and RANKL in vitro and histomorphometric indices of bone turnover in patients with different bone diseases. J Bone Miner Res 2003, 18:529-38.
• [25]Pfeilschifter J: Role of cytokines in postmenopausal bone loss. Curr Osteoporos Rep 2003, 1:53-8.
• [26]Manolagas SC, Jilka RL: Bone marrow, cytokines, and bone remodeling. Emerging insights into the pathophysiology of osteoporosis. N Engl J Med 1995, 332:305-11.
• [27]Manolagas SC: Birth and death of bone cells: basic regulatory mechanisms and implications for the pathogenesis and treatment of osteoporosis. Endocr Rev 2000, 21:115-137.
• [28]Takayanagi H, Ogasawara K, Hida S, Chiba T, Murata S, Sato K, Takaoka A, Yokochi T, Oda H, Tanaka K, Nakamura K, Taniguchi T: T-cell-mediated regulation of osteoclastogenesis by signalling cross-talk between RANKL and IFN-gamma. Nature 2000, 408:600-5.
• [29]Wei S, Kitaura H, Zhou P, Ross FP, Teitelbaum SL: IL-1 mediates TNF-induced osteoclastogenesis. J Clin Invest 2005, 115:282-90.
• [30]Pacifici R, Rifas L, McCracken R, Vered I, McMurtry C, Avioli LV, Peck WA: Ovarian steroid treatment blocks a postmenopausal increase in blood monocyte interleukin 1 release. Proc Natl Acad Sci USA 1989, 86:2398-2402.
• [31]Moffett SP, Zmuda JM, Oakley JI, Beck TJ, Cauley JA, Stone KL, Lui LY, Ensrud KE, Hillier TA, Hochberg MC, Morin P, Peltz G, Greene D, Cummings SR: Tumor necrosis factor-alpha polymorphism, bone strength phenotypes, and the risk of fracture in older women. J Clin Endocrinol Metab 2005, 90:3491-7.
• [32]Scheidt-Nave C, Bismar H, Leidig-Bruckner G, Woitge H, Seibel MJ, Ziegler R, Pfeilschifter J: Serum interleukin 6 is a major predictor of bone loss in women specific to the first decade post menopause. J Clin Endocrinol Metab 2001, 86:2032-42.
• [33]Armour KJ, Armour KE, van't Hof RJ, Reid DM, Wei XQ, Liew FY, Ralston SH: Activation of the inducible nitric oxide synthase pathway contributes to inflammation-induced osteoporosis by suppressing bone formation and causing osteoblast apoptosis. Arthritis Rheum 2001, 44:2790-6.
• [34]Romas E, Gillespie MT, Martin TJ: Involvement of receptor activator of NFkappaB ligand and tumor necrosis factor-alpha in bone destruction in rheumatoid arthritis. Bone 2002, 30:340-6.
• [35]Theill LE, Boyle WJ, Penninger JM: KANK-L and RANK: T cells, bone loss, and mammalian evolution. Annu Rev Immunol 2002, 20:795-823.
• [36]Eghbali-Fatourechi G, Khosla S, Sanyal A, Boyle WJ, Lacey DL, Riggs BL: Role of RANK ligand in mediating increased bone resorption in early postmenopausal women. J Clin Invest 2003, 111:1221-30.
• [37]Teitelbaum SL: Osteoclasts, integrins, and osteoporosis. J Bone Miner Metab 2000, 18:344-9.
• [38]Wu H, Arron JR: TRAF6, a molecular bridge spanning adaptive immunity, innate immunity and osteoimmunology. BioEssays 2003, 25:1096-1105.
• [39]Lomaga MA, Yeh WC, Sarosi I, Duncan GS, Furlonger C, Ho A, Morony S, Capparelli C, Van G, Kaufman S, van der Heiden A, Itie A, Wakeham A, Khoo W, Sasaki T, Cao Z, Penninger JM, Paige CJ, Lacey DL, Dunstan CR, Boyle WJ, Goeddel DV, Mak TW: TRAF6 deficiency results in osteopetrosis and defective interleukin-1, CD40, and LPS signaling. Genes Dev 1999, 13:1015-24.
• [40]Hofbauer LC, Lacey DL, Dunstan CR, Spelsberg TC, Riggs BL, Khosla S: Interleukin-1beta and tumor necrosis factor-alpha, but not interleukin-6, stimulate osteoprotegerin ligand gene expression in human osteoblastic cells. Bone 1999, 25:255-9.
• [41]Wallin R, Wajih N, Greenwood GT, Sane DC: Arterial calcification: a review of mechanisms, animal models, and the prospects for therapy. Med Res Rev 2001, 21:274-301.
• [42]Hirose K, Tomiyama H, Okazaki R, Arai T, Koji Y, Zaydun G, Hori S, Yamashina A: Increased pulse wavevelocity associated with reduced calcaneal quantitative osteo-sono index: possible relationship between atherosclerosis and osteopenia. J Clin Endocrinol Metab 2003, 88:2573-2578.
• [43]Bruunsgaard H, Pedersen BK: Age-related inflammatory cytokines and disease. Immunol Allergy Clin North Am 2003, 23:15-39.
• [44]Ginaldi L, De Martinis M, Monti D, Franceschi C: Chronic antigenic load and apoptosis in immunosenescence. Trends Immunol 2005, 26:79-84.
• [45]Bruunsgaard H: Effects of tumor necrosis factor-alpha and interleukin-6 in elderly populations. Eur Cytokine Netw 2002, 13:389-391.
• [46]Hak AE, Pols HA, van Hemert AM, Hofman A, Witteman JC: Progression of aortic calcification is associated with metacarpal bone loss during menopause: a population-based longitudinal study. Arterioscler Thromb Vasc Biol 2000, 20:1926-1931.
• [47]Jorgensen L, Engstad T, Jacobsen BK: Bone mineral density in acute stroke patients: low bone mineral density may predict first stroke in women. Stroke 2001, 32:47-51.
• [48]Roubenoff R: Catabolism of aging: is it an inflammatory process? Curr Opin Clin Nutr Metab Care 2003, 6:295-299.
• [49]Ferrari SL, Ahn-Luong L, Garnero P, Humphries SE, Greenspan SL: Two promoter polymorphisms regulating interleukin-6 gene expression are associated with circulating levels of C-reactive protein and markers of bone resorption in postmenopausal women. J Clin Endocrinol Metab 2003, 88:255-259.
• [50]Chen HY, Chen WC, Wu MC, Tsai FJ, Lin CC: Interleukin-1beta and interleukin-1 receptor antagonist gene polymorphism in postmenopausal women: correlation to bone mineral density and susceptibility to osteoporosis. Maturitas 2002, 44:49-54.
• [51]Liu H, Liu K, Bodenner DL: Estrogen receptor inhibits interleukin-6 gene expression by disruption of nuclear factor kappa B transactivation. Cytokine 2005, 31:251-257.
• [52]Pfeilschifter J, Koditz R, Pfohl M, Schatz H: Changes in proinflammatory cytokine activity after menopause. Endocr Rev 2002, 23:90-119.
• [53]Ershler W, Harman SM, Keller ET: Immunologic aspects of osteoporosis. Dev Comp Immunol 1997, 21:487-499.
• [54]De Martinis M, Franceschi C, Monti D, Ginaldi L: Inflamm-ageing and lifelong antigenic load as major determinants of ageing rate and longevity. FEBS Lett 2005, 579:2035-2039.